REG - Eco Animal Health Gp - Change of Auditor

ECO Animal HealthAnnouncement

14/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221114:nRSN2248Ga&default-theme=true

RNS Number : 2248G  Eco Animal Health Group PLC  14 November 2022

14 November 2022

ECO Animal Health Group plc

(the "Company" or the "Group") (AIM: EAH)

 

Change of Auditor

 

Following a competitive tender process overseen by the Group's Audit &
Risk Committee, the Company announces the resignation of BDO LLP as auditor
and the appointment, with immediate effect, of Haysmacintyre LLP as auditor
for the financial year ending 31 March 2023. Haysmacintyre's re-appointment
for the subsequent financial year will be subject to approval by shareholders
at the next Annual General Meeting of the Company to be held in 2023.

 

The Group's Audit & Risk Committee decided to undertake a formal audit
tender process following the end of the last financial period. BDO LLP has
deposited with the Company a statement confirming that there are no matters to
be brought to the attention of the Company's members or creditors.

 

For further information, please contact:

 

Contacts:

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)

 IFC Advisory                                                   020 3934 6630

 Graham Herring

 Zach Cohen

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Mark Taylor

 George Tzimas

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Brough Ransom

 Carlo Spingardi

 Peel Hunt LLP (Joint Broker)                                   020 7418 8900

 Dr Christopher Golden

James Steel

 

 Equity Development   020 7065 2692

 Hannah Crowe

 Matt Evans

 

 

 

 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products
for livestock. Our business strategy is to generate shareholder value by
achieving the maximum sales potential from the existing product portfolio
whilst investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFZMMMMFKGZZZ